2026³â 02¿ù 18ÀÏ ¼ö¿äÀÏ
 
 
  ÇöÀçÀ§Ä¡ > ´º½ºÁö´åÄÄ > Science & Technology

·£¼¶¿þ¾îºÎÅÍ µÅÁöµµ»ì±îÁö... ³ë·ÃÇØÁø »ç±âÇà°¢

 

Á¤Ä¡

 

°æÁ¦

 

»çȸ

 

»ýȰ

 

¹®È­

 

±¹Á¦

 

°úÇбâ¼ú

 

¿¬¿¹

 

½ºÆ÷Ã÷

 

ÀÚµ¿Â÷

 

ºÎµ¿»ê

 

°æ¿µ

 

¿µ¾÷

 

¹Ìµð¾î

 

½Å»óǰ

 

±³À°

 

ÇÐȸ

 

½Å°£

 

°øÁö»çÇ×

 

Ä®·³

 

Ä·ÆäÀÎ
Çѻ츲 ¡®¿ì¸®´Â ÇѽҸ²¡¯ ½Ò ¼Òºñ Ä·ÆäÀÎ ½Ã...
1000¸¸¿øÂ¥¸® Àΰø¿Í¿ì, °Ç°­º¸Çè Áö¿ø ¡®Æò...
- - - - - - -
 

Famenity's Brain Factor-7¢ç Gains Global Momentum as Clinically Validated Ingredient for Cognitive Health

´º½ºÀÏÀÚ: 2026-01-03

SEOUL -- Famenity Co., Ltd., a South Korean research and development company specializing in functional ingredients for health supplements, said that its Brain Factor-7® (BF-7®) is drawing attention among global brands seeking clinical-grade cognitive-support ingredients.

BF-7®, a silk-peptide complex, is backed by over 12 independent human studies across the entire lifespan, from children and students to adults and seniors. The findings collectively confirm BF-7®’s benefits for memory, learning ability, cognitive performance, focus, and mental resilience, establishing BF-7® as one of the most comprehensively validated natural cognitive-health ingredients available today. BF-7® is supported by multiple global regulatory recognitions, led first by its listing as a U.S. FDA New Dietary Ingredient (NDI). It is also licensed through Health Canada (NPN), acknowledged by the Ministry of Food and Drug Safety (MFDS) in Korea as an Individually Recognized Functional Ingredient, and certified Halal, making it suitable for the global market. As demand in North America and Europe shifts toward clean-label, non-stimulant nootropics with real clinical evidence, BF-7® stands out thanks to its derivation: a low-molecular-weight silk fibroin peptide complex refined through Famenity’s proprietary enzymatic hydrolysis.

Recent interest has been further driven by BF-7®’s mechanistic profile. Research indicates that BF-7® strengthens neuronal network functioning, supports acetylcholine modulation, reduces oxidative stress, and helps protect neurons from environmental and psychological stressors—mechanistic advantages increasingly valued by supplement formulators and functional-beverage developers.

Finished products containing BF-7® are already distributed across the United States, Canada, Europe, and Asia, reflecting strong commercial acceptance and global scalability. Beyond BF-7®, Famenity has built a broad portfolio of clinically grounded functional ingredients. These include MS-10®, a patented botanical complex supporting women’s menopausal comfort; MR-10®, a men’s vitality and performance formulation; GinsaMin®, a U.S. FDA NDI-listed ginseng-derived compound; TamiSense® (Live EGF), a premium bioactive solution utilizing live EGF for skin regeneration; YES-10®, a mental-wellness ingredient targeting stress balance; and TEES-10®, a dental and oral-health complex. This diverse ingredient platform—spanning cognitive health, women’s and men’s health, skin renewal, mental wellness, and oral care—highlights Famenity’s position as a science-driven innovator in global functional material development.

The company stated that with the global brain-health market rapidly expanding across all age groups, it remains committed to delivering safe, validated, and industry-ready functional ingredients to international partners.



 Àüü´º½º¸ñ·ÏÀ¸·Î

Celonis Process Intelligence Helps Fujitsu Improve Inventory Management and Enable AI-Driven Transformation
New Experian Study Reveals Critical Role of AI in Lending and Key Drivers of Accelerated Adoption by Financial Institutions
Rimini Street Earns Industry Honors for AI Innovation, Client Focus, Technical Excellence and Business Impact
Lenovo Brings Real-Time Store Visibility and AI-Driven Support to Retail—Delivering Value on Day One
Blue Shift Report Highlights Systemic Vulnerabilities Caused by the Hidden Cost of AI
Australian Defence Force Secures Satellite Communications on SES IS-22
BlueMatrix and Perplexity Partner to Bring AI-Powered Discovery to Institutional Research

 

KIOXIA SSDs Achieve Compatibility with Microchip¡¯s Adaptec¢ç SmartRAI...
FDA Accepts New Drug Application for Pimicotinib for the Treatment of ...
ACCELQ Crowned Leader and Customer Favorite in The Forrester Wave¢â fo...
Rigaku Launches ONYX 3200, a Metrology Instrument for Semiconductor Ma...
IntelliVIX Showcases ¡®K-AI¡¯ Prowess at CES 2026, Accelerating Global...
BeOne Medicines Highlights Global Oncology Leadership at 44th Annual J...
Interactive Brokers Redesigns IBKR GlobalTrader App for Simpler, Smart...

 


°øÁö»çÇ×
´º½ºÁö ÇÑÀÚ Ç¥±â¿¡ ´ë¸¸½Ä À½Â÷ Ç¥±â '纽ÞÙó¢ ´Ï¿ì½ÃÁö' º´±â
º£³×ÇÁ·Ò º£³×ÀÎÅõ Áß¹® Ç¥±â 宝Ò¬ÜØÙÌ 宝Ò¬ì×öõ(ÜÄÒ¬ÜØÙÌ ÜÄ...
¹Ìµð¾î¾Æ¿ì¾î Mediaour ØÚ体ä²们 ØÚô÷ä²Ùú MO ¿¥¿À ØÚä² ØÚä²
¾Ë¸®¿ìºê Alliuv ä¹备, ¾Ë¶ã Althle ä¹÷åìÌ
¾Ë¸®¾Ë Allial Áß¹® Ç¥±â ä¹××尔 ä¹××ì³
´ºÆÛ½ºÆ® New1st Áß¹® Ç¥±â 纽ììãæ(¹øÃ¼ Òïììãæ), N1 纽1
¿£ÄÚ½º¸ð½º : À̾¾ 'EnCosmos : EC' Áß¹® Ç¥±â ì¤ñµ
¾ÆÀ̵ð¾î·Ð Idearon Áß¹® Ç¥±â ì¤îè论 ì¤îèÖå
¹ÙÀÌ¿ÀÀÌ´Ï Bioini Áß¹® Ç¥±â ù±药研 ù±å·æÚ
¿À½ºÇÁ·Ò Ausfrom 奥ÞÙÜØÙÌ, À£ÇÁ·Ò Welfrom 卫ÜØÙÌ
¿¡³ÊÇÁ·Ò Enerfrom 额ÒöÜØÙÌ ¿¡³ÊÀ¯ºñ Eneruv 额Òöêó备
¾ËÇÁ·Ò Alfrom Áß¹® Ç¥±â ä¹尔ÜØÙÌ ä¹ì³ÜØÙÌ

 

ȸ»ç¼Ò°³ | ÀÎÀçä¿ë | ÀÌ¿ë¾à°ü | °³ÀÎÁ¤º¸Ãë±Þ¹æÄ§ | û¼Ò³âº¸È£Á¤Ã¥ | Ã¥ÀÓÇѰè¿Í ¹ýÀû°íÁö | À̸ÞÀÏÁÖ¼Ò¹«´Ü¼öÁý°ÅºÎ | °í°´¼¾ÅÍ

±â»çÁ¦º¸ À̸ÞÀÏ news@newsji.com, ÀüÈ­ 050 2222 0002, ÆÑ½º 050 2222 0111, ÁÖ¼Ò : ¼­¿ï ±¸·Î±¸ °¡¸¶»ê·Î 27±æ 60 1-37È£

ÀÎÅͳݴº½º¼­ºñ½º»ç¾÷µî·Ï : ¼­¿ï ÀÚ00447, µî·ÏÀÏÀÚ : 2013.12.23., ´º½º¹è¿­ ¹× û¼Ò³âº¸È£ÀÇ Ã¥ÀÓ : ´ëÇ¥ CEO

Copyright ¨Ï All rights reserved..